Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD

EHA Congress 2022

9 - 12 Jun 2022

Published: 13 Jun 2022

Views: 110

Rating:

Save

Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy

Prof Franco Locatelli presents data from the CLIMB THAL-111 and CLIMB SCD-121 studies during a press conference at the EHA 2022 meeting.

The studies aimed to evaluate the efficacy and safety of exa-cel in 44 patients with transfusion-dependent beta-thalassemia (TDT) and 31 patients with sickle cell disease (SCD).

Read the news story here

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

Choosing wisely in multiple myeloma

Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal

Choosing wisely in multiple myeloma ( Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal )

More from ecancer